Glycylcyclines

Glycylcyclines are a class of antibiotics that were developed in response to the growing rate of bacterial resistance to existing antibiotics. They are derived from tetracycline antibiotics and are designed to overcome two common mechanisms of tetracycline resistance.

History[edit | edit source]

The first glycylcycline, tigecycline, was approved by the FDA in 2005. It was developed by Wyeth (now part of Pfizer) and is marketed under the brand name Tygacil.

Mechanism of action[edit | edit source]

Glycylcyclines work by binding to the 30S ribosomal subunit of bacteria, which prevents the attachment of aminoacyl-tRNA to the ribosome. This inhibits protein synthesis and thus prevents the bacteria from growing and multiplying.

Resistance[edit | edit source]

Resistance to glycylcyclines can occur through several mechanisms, including efflux pumps and ribosomal protection proteins. However, because of their design, glycylcyclines are less susceptible to these resistance mechanisms than other tetracyclines.

Clinical use[edit | edit source]

Glycylcyclines are used to treat a variety of infections, including skin and skin structure infections, intra-abdominal infections, and community-acquired pneumonia. They are also used in situations where other antibiotics are ineffective due to resistance.

Side effects[edit | edit source]

Common side effects of glycylcyclines include nausea, vomiting, and diarrhea. More serious side effects can include pancreatitis, liver toxicity, and an increased risk of death compared to other antibiotics.

See also[edit | edit source]

Glycylcyclines Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.